MedTrace Logo

Phase II Study of Second- Line Pembrolizumab Plus GVD for Relapsed or Refractory Hodgkin Lymphoma

NCT03618550 · Status: RECRUITING · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 257

Last updated 2026-08-07

No results posted yet for this study

Summary

The purpose of this study is to test any good and bad effects of the study drug, pembrolizumab, in combination with GVD in the treatment of Hodgkin lymphoma.

Conditions

Interventions

DRUG

pembrolizumab

Age 10-17: 2mg/kg (cap at 200mg), Age ≥ 18: 200 mg (flat) ,Day 1 of each 3 week cycle IV infusion 2-4 cycles (pre-ASCT)

DRUG

gemcitabine

1000mg/m\^2 Days 1 and 8 of each 3 week cycle IV infusion 2-4 cycles

DRUG

vinorelbine

20mg/m\^2 Days 1 and 8 of each 3 week cycle IV infusion 2-4 cycles

DRUG

liposomal doxorubicin

15mg/m\^2 Days 1 and 8 of each 3 week cycle IV infusion 2-4 cycles

PROCEDURE

Stem cell mobilization and collection

Stem cell mobilization and collection will be performed as per standard MSKCC guidelines after 2-4 cycles of pembrolizumab-GVD.

RADIATION

Involved-site radiation therapy

Involved-site radiation therapy (ISRT) Patients with limited sites of disease prior to initiation of pembro-GVD are eligible to receive ISRT prior to ASCT or with pembrolizumab maintenance. n. ISRT to nodal based disease should be delivered in line with the guidelines provided by the International Lymphoma Radiation Oncology Group.

Sponsors & Collaborators

Principal Investigators

  • Alison Moskowitz, MD · Memorial Sloan Kettering Cancer Center

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2018-08-01
Primary Completion
2027-08-31
Completion
2027-08-31
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs
Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03618550 on ClinicalTrials.gov